Hôpital Foch will test a technology developed by start-up surgeons to predict post-surgical complications

In 2022, Fuchs Hospital in Surrey will test and verify a test that predicts the risk of post-surgical complications for patients undergoing digestive surgery. Already tested in the United States, the technology of the French start-up Surge will be deployed during this innovative scientific collaboration.

More than 8.5 million surgeries are performed each year in France. About thirty percent (30%) of these operations are due to postoperative complications such as infections, cognitive impairment, and thromboembolic accidents. These complications usually require extra care or hospitalization and can have serious consequences in some cases.

A test that assesses the state of the immune system in patients before surgery

The Surg team developed an experiment to calculate the likelihood of developing postoperative complications from a patient’s blood sample taken before surgery. By combining the biological analysis of its immune system with an artificial intelligence algorithm, Serge is thus able to provide for each individual the potential risk of surgical complications.

Depending on the test results, preventive management strategies may be proposed by physicians to improve patient readiness before surgery. The goal is to optimize the course of care to reduce the risk of postoperative complications.

To evaluate this algorithm, Serge is joining forces with Foch Hospital to run a multicenter potential clinical trial. The various departments at Foch Hospital come together to create protocols, make appropriate systematic choices, and select patients.

On the one hand, the Department of Anesthesia-Resuscitation and Digestive Surgery and the FOCH Clinical Research and Innovation Delegation (DRCI) pool their medical, surgical and clinical research expertise. On the other hand, the Department of Epidemiology – Data – Biostatistics (EDB) and Foch’s Medical Device Innovation Center (CIDM) participate in the clinical evaluation of this experiment to anticipate marketing phases.

Clinical Trial: An Essential Prerequisite for Getting CE Marking for Marketing of this Test

A first clinical trial with 41 American patients undergoing large abdominal surgery showed that the test achieved a sensitivity of 80% compared to 30% of current clinical scales. In other words, this test is two to three times more reliable than the existing test. This unparalleled performance paints a picture of a revolution in the personalization of perioperative medicine. “Our goal is to confirm the results of our first clinical study on a population of hundreds of patients, involving several hospitals.AAs Sergeant’s CEO explains,

This clinical trial, conducted in partnership with Foch Hospital, will evaluate the performance of this health technology. This step is essential to ensure the effectiveness and safety of this test and thus enable the marketing of this innovation to be able to obtain CE marking.

A patent solution has been created between the United States and France

Established in August 2021 in France by six associates, engineers and physicians from Stanford University, Sorbonne University and Ecole Polytechnic, Surge’s technology is based on a ten-year study of the risk of surgery performed at Stanford University’s Dr. Bryce Gaudlier’s laboratory. Serge is hosted in the Agoranov incubator and benefits from the support of 50 partner accelerators. “Our goal is to make this innovation accessible in the healthcare system for the benefit of patients. A Serge’s CEO Julien Hedu summed it up.

For several years, so-called “predictive” drugs have been searching for reliable biomarkers to determine the patient’s near future. The tool offered by Startup Surge is easy to obtain and attempts to go beyond a single molecule by offering an extensive screening with artificial intelligence. So legitimizing it with a large population of operated patients is an exciting challenge.6, Dr. Morgan Le Nguyen, head of the anesthesia department at Foch Hospital.

About Foch Hospital:

Hôpital Foch is one of the largest hospitals in -le-de-France, with a staff of 2,300, including more than 300 doctors, 611 beds installed, 260,000 consultations excluding maternity and emergency and more than 60,000 hospital admissions each year. -France 6

Its high level of multi-disciplinary care in almost all adult medicine and surgery, its strong involvement in education, training and research, its state-of-the-art medico-technical platform, welcoming tradition make it one of the most successful private non-profit hospitals in France.

The Franco-American FOCH Foundation, which built and built FOCH Hospital, is still an important player in its management and strategic choices in its activities. Most of its services enjoy high and fast growing presence.


About Serge:

The purpose of Surg is to predict postoperative complications in order to optimize the management of patients through surgery. Our team developed a test to identify patients at risk for complications. The experiment is based on the results of more than ten years of research in the laboratory of Dr. Bryce Gaudillier at Stanford University.

By estimating the risks associated with the operation and allowing patients to adapt the care path as much as possible to their needs, this innovation promises to revolutionize the quality of surgical care and the patient experience.

Our team shares a common vision centered on innovation in the field of health: developing a service designed to benefit patient needs and the healthcare system as a whole. https://www.surge2surgery.com/

Photo Credit: DepositPhotos

Leave a Comment